Article Data

  • Views 630
  • Dowloads 138

Original Research

Open Access

Increased incidence of advanced stage endometrial cancer: a retrospective analysis of different clinical approaches and tumour biology

  • M. Pakiž1
  • A. Dovnik1,*,
  • B. Crnobrnja1
  • P. Zola2

1University Clinic for Gynaecology and Perinatology, University Medical Center Maribor, Maribor (Slovenia)

2Departement of Surgical Sciences, University of Torino, Torino (Italy)

DOI: 10.31083/j.ejgo.2020.02.5170 Vol.41,Issue 2,April 2020 pp.246-251

Published: 15 April 2020

*Corresponding Author(s): A. Dovnik E-mail: andrazdovnik@gmail.com

Abstract

Introduction: An increasing percentage of advanced FIGO Stage has been observed among endometrial cancer patients referred to this department within the last five years. During the same time period, the diagnostic method used changed from D&C to office hysteroscopy (HSC) with a prolongation of waiting times for biopsy and surgery. The authors analyzed potential reasons for increased percentage of advanced stage disease. Materials and Methods: 499 consecutive new endometrial cancer patients were included from 2005 to 2015. The authors analyzed characteristics of the, diagnostic method, waiting times for biopsy and surgery, occurrence, duration of abnormal uterine bleeding (AUB), and hormonal treatment (gestagen) for AUB. A comparison between FIGO Stage I vs. II or more was performed. Results: The increase in advanced FIGO Stage disease was significant. Characteristics other than stage did not significantly change. The duration of AUB was the same. Gestagen for AUB was used almost three-fold more often during the last two years. Comparison between FIGO Stage I vs. II or more showed the stage was solely associated with tumor biology. Conclusions: The FIGO Stage of the disease was associated with more aggressive tumours whereas the diagnostic method, prolonged waiting times for biopsy and surgery, and a more conservative approach to AUB or several years of history of AUB were not associated with advanced disease.

Keywords

Endometrial carcinoma; FIGO staging; Hysteroscopy; Dilatation and curettage; Time to diagnosis.

Cite and Share

M. Pakiž,A. Dovnik,B. Crnobrnja,P. Zola. Increased incidence of advanced stage endometrial cancer: a retrospective analysis of different clinical approaches and tumour biology. European Journal of Gynaecological Oncology. 2020. 41(2);246-251.

References

[1] Cancer Registry of the Republic of Slovenia. Ljubljana: Institute of Oncology, 2017. Available at: https://www.onko-i.si/rrs/

[2] Cancer Research UK. London: Cancer Research UK, 2017. Available at: http://www.cancerresearchuk.org

[3] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: “Global cancer statistics 2012”. CA Cancer J. Clin., 2015, 65, 87.

[4] Felix A.S., Weissfeld J.L., Stone R.A., Bowser R., Chivukula M., Edwards R.P., Linkov F.: “Factors associated with Type I and Type II endometrial cancer”. Cancer Causes Control, 2010, 21, 1851.

[5] Kimura T., Kamiura S., Yamamoto T., Seino-Noda H., Ohira H., Saji F.: “Abnormal uterine bleeding and prognosis of endometrial cancer”. Int. J. Gynaecol. Obstet., 2004, 85, 145.

[6] Seebacher V., Schmid M., Polterauer S., Hefler-Frischmuth K., Leipold H., Concin N., et al.: “The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study”. BMC Cancer, 2009, 9, 460.

[7] Yazbeck C., Dhainaut C., Batallan A., Benifla J.L., Thoury A., Madelenat P.: “Diagnostic hysteroscopy and risk of peritoneal dissemination of tumor cells”. Gynecol. Obstet. Fertil., 2005, 33, 247.

[8] Ben-Arie A., Tamir S., Dubnik S., Gemer O., Ben Shushan A., Dgani R., et al.: “Does hysteroscopy affect prognosis in apparent earlystage endometrial cancer”? Int. J. Gynecol. Cancer, 2008, 18, 813.

[9] Epstein E., Ramirez A., Skoog L., Valentin L.: “Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding”. Acta Obstet. Gynecol. Scand., 2001, 80, 1131.

[10] Gimpelson R.J., Rappold H.O.: “A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases”. Am. J. Obstet. Gynecol., 1988, 158, 489.

[11] Deckardt R., Lueken R.P., Gallinat A., Möller C.P., Busche D., Nugent W., et al.: “Comparison of transvaginal ultrasound, hysteroscopy, and dilatation and curettage in the diagnosis of abnormal vaginal bleeding and intrauterine pathology in perimenopausal and postmenopausal women”. J. Am. Assoc. Gynecol. Laparosc., 2002, 9, 277.

[12] Smith-Bindman R., Weiss E., Feldstein V.: “How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding”. Ultrasound Obstet. Gynecol., 2004, 24, 558.

[13] Beral V., Bull D., Reeves G.: “Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study”. Lancet, 2005, 365, 1543.

[14] Chu J., Schweid A.I., Weiss N.S.: “Survival among women with endometrial cancer: a comparison of estrogen users and nonusers”. Am. J. Obstet. Gynecol., 1982, 143, 569.

[15] Iqbal J., Ginsburg O.M., Wijeratne T.D., Howell A., Evans G., Sestak I., Narod S.A.: “Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review”. Cancer Treat Rev., 2012, 38, 318.

[16] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C., Godwin J., Grey R., Clarke M., Cutter D., Darby S., et al.: “Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials”. Lancet, 2011, 378, 771.

[17] Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M.: “Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14”. J Natl. Cancer Inst., 1994, 86, 527.

[18] Barakat R.R., Wong G., Curtin J.P., Vlamis V., Hoskins W.J.: “Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features”. Gynecol Oncol., 1994, 55, 164.

[19] The NHS in England. London: National Health Service UK, 2017. Available at: https://www.england.nhs.uk/statistics/ statistical workareas/cancer-waiting-times/. [20] Dijkhuizen F.P., Mol B.W., Brölmann H.A., Brölmann H.A., Heintz A.P.: “The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis”. Cancer, 2000, 89, 1765.

[21] Clark T.J., Mann C.H., Shah N., Khan K.S., Song F., Gupta J.K.: “Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review”. BJOG, 2002, 109, 313.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top